Multidisciplinary Sleep Unit, Respiratory Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Drug Research Center, Institute for Biomedical Research Sant Pau (IIB Sant Pau), Department of Pharmacology and Therapeutics, Universitat Autònoma de Barcelona, Barcelona, Spain.
J Clin Sleep Med. 2018 Oct 15;14(10):1725-1733. doi: 10.5664/jcsm.7382.
Sleep problems are often undetected in adults with Down syndrome (DS). Our objective was to determine the prevalence of sleep disorders in adults with DS through self-reported and objective sleep measures.
We performed a community-based cross-sectional study of 54 adults with DS not referred for sleep disorders. Two polysomnography (PSG) sleep studies were performed. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI); daytime sleepiness was evaluated using the Epworth Sleepiness Scale (ESS) and the risk for the sleep apnea syndrome (OSA) was identified using the Berlin Questionnaire (BQ). Participants' sleep/wake pattern was assessed from sleep diaries and by wrist actigraphy. PSQI, ESS, and PSG measures were compared with 35 sex-, age-, and body mass index-matched patients in the control groups.
In PSG measures, adults with DS showed lower sleep efficiency (69 ± 17.7 versus 81.6 ± 11; < .001), less rapid eye movement sleep (9.4 ± 5.8 versus 19.4 ± 5.1; < .001), a higher prevalence of OSA (78% versus 14%; < .001), and a higher apnea-hypopnea index (23.5 ± 24.5 versus 3.8 ± 10.5; < .001) than patients in the control group. In the DS group, the questionnaires (mean PSQI 3.7 ± 2.9; mean ESS 6.3 ± 4.5 and mean BQ 1 ± 0) did not reflect the sleep disturbances detected on the PSG. Actigraphy data recorded daytime sleep that was not self-reported (118.2 ± 104.2 minutes).
Adults with DS show severe sleep disruption and a high prevalence of OSA, undetected by self-reported sleep measures. Actigraphy, PSG, and validated simplified devices for screening OSA should be routinely recommended for this population because treatment of sleep disorders can contribute to healthy aging.
唐氏综合征(DS)患者的睡眠问题常未被发现。我们的目的是通过自我报告和客观的睡眠测量来确定 DS 成人的睡眠障碍患病率。
我们对 54 名未因睡眠障碍就诊的 DS 成人进行了一项基于社区的横断面研究。进行了两次多导睡眠图(PSG)睡眠研究。使用匹兹堡睡眠质量指数(PSQI)评估睡眠质量;使用 Epworth 嗜睡量表(ESS)和柏林问卷(BQ)评估睡眠呼吸暂停综合征(OSA)风险。使用睡眠日记和腕部活动记录仪评估参与者的睡眠/觉醒模式。将 PSQI、ESS 和 PSG 测量值与对照组中 35 名性别、年龄和体重指数匹配的患者进行比较。
在 PSG 测量中,DS 成人的睡眠效率较低(69 ± 17.7 与 81.6 ± 11;< 0.001),快速眼动睡眠较少(9.4 ± 5.8 与 19.4 ± 5.1;< 0.001),OSA 患病率较高(78%与 14%;< 0.001),呼吸暂停低通气指数较高(23.5 ± 24.5 与 3.8 ± 10.5;< 0.001)比对照组患者。在 DS 组中,问卷(平均 PSQI 3.7 ± 2.9;平均 ESS 6.3 ± 4.5 和平均 BQ 1 ± 0)并未反映 PSG 上检测到的睡眠障碍。活动记录仪数据记录了未自我报告的日间睡眠(118.2 ± 104.2 分钟)。
DS 成人表现出严重的睡眠障碍和 OSA 的高患病率,这些问题无法通过自我报告的睡眠测量来发现。应常规推荐活动记录仪、PSG 和用于筛查 OSA 的简化验证设备,因为治疗睡眠障碍可以促进健康老龄化。